In reconstructive surgery, specifically free flap reconstructive surgery, concerns persist regarding the risk of failures due ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Patients with chronic kidney disease (CKD) often encounter cardiovascular complications, most commonly ...

Patients with chronic kidney disease (CKD) often encounter cardiovascular complications, most commonly coronary heart disease. Although coronary artery bypass grafting is an effective treatment for ...

The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...

Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...

The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...

Chronic Kidney Disease and Cognitive Dysfunction after Cardiac Surgery. CVIA. 2025. Vol. 10 (1). DOI: 10.15212/CVIA.2024.0068 /Public Release. This material from the originating organization/author (s ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...